Antiviral Drugs - Central Asia

Central Asia

The projected revenue for the Antiviral Drugs market in Central Asia is expected to reach US$48.84m by 2024.
It is anticipated that the revenue will exhibit an annual growth rate of 3.03% between 2024 and 2029, resulting in a market volume of US$56.69m by 2029.
When compared globally, United States is expected to generate the highest revenue, amounting to US$30,640.00m in 2024.
In Central Asia, there is an increasing demand for antiviral drugs as the region experiences a rise in viral infections.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for Antiviral Drugs in Central Asia has been on the rise in recent years.

Customer preferences: The customers in Central Asia are more inclined towards the consumption of generic antiviral drugs due to their cost-effectiveness. Moreover, the rising cases of viral infections such as Hepatitis B and C, HIV, and COVID-19 have increased the demand for antiviral drugs in the region.

Trends in the market: Kazakhstan is the largest market for antiviral drugs in Central Asia, followed by Uzbekistan and Kyrgyzstan. The demand for antiviral drugs in Kazakhstan is driven by the high prevalence of Hepatitis B and C in the country. On the other hand, the demand for antiviral drugs in Uzbekistan is driven by the high prevalence of HIV and Hepatitis C. In Kyrgyzstan, the demand for antiviral drugs is driven by the increasing cases of COVID-19.

Local special circumstances: The availability of antiviral drugs in the region is limited due to the lack of domestic production and dependency on imports. This has resulted in high prices of antiviral drugs, making it inaccessible to a large section of the population. Moreover, the lack of awareness about the importance of antiviral drugs in treating viral infections is another factor hindering the growth of the market.

Underlying macroeconomic factors: The economic growth in Central Asia has been sluggish in recent years, resulting in a decrease in the purchasing power of the population. This has led to a shift in the consumer behavior towards cost-effective generic drugs. Moreover, the increasing government initiatives to provide affordable healthcare to the population have also contributed to the growth of the antiviral drugs market in the region.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.